

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS VI LLC  
Petitioner,

v.

CELGENE CORPORATION  
Patent Owner

---

Case IPR2015-01169  
Patent 5,635,517

---

**PATENT OWNER EXHIBIT LIST AS OF  
August 19, 2015 PURSUANT TO 37 C.F.R. § 42.63(e)**

EXHIBIT NO.	DESCRIPTION
Exhibit 2001	Dr. V. Pannikar, WHO, "The Return of Thalidomide: New Uses and Renewed Concerns."
Exhibit 2002	FDA website, "About the FDA;" (2014).
Exhibit 2003	Smith, R.L. et al. "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds;" (1965).
Exhibit 2004	Jonsson, N. Ake, "Chemical structure and teratogenic properties" (1972).
Exhibit 2005	Powell, R.J. "New roles for thalidomide: A unique anti-inflammatory, but use it only when no alternatives exist;" (1996).
Exhibit 2006	'517 File History, Notice of References Cited (1997).
Exhibit 2007	'517 File History, Information Disclosure Citation (1997).
Exhibit 2008	U.S. Patent No. 5,712,291 (1998).
Exhibit 2009	Intentionally left blank
Exhibit 2010	Janeway, Charles, et al. "Immuno Biology 5: The Immune System in Health and Diseases;" (2001).
Exhibit 2011	Medzhitov, Ruslan "Origin and physiological roles of inflammation;" (2008).
Exhibit 2012	Bedarida, Gabriella, et al. "Pharmacodynamics and Drug Action H <sub>1</sub> - and H <sub>2</sub> -hystamine receptor – mediated vasodilation varies with aging in humans;" (1995).
Exhibit 2013	Van Nueten, J.M., et al. "Serotonin and Vascular Reactivity;" (1985).
Exhibit 2014	Swartz, Stephen "The Role of Prostaglandins in Mediating the Effects of Angiotensin Converting Enzyme Inhibitors and Other Antihypertensive Drugs;" (1987).
Exhibit 2015	Bode-Boger, Stefanie, et al. "L-Arginine Induces Nitric Oxide–Dependent Vasodilation in Patients With Critical Limb Ischemia;" (1996).
Exhibit 2016	Larkin, S.W. et al. "Prolonged Microvascular Vasodilation Induced by Leukotriene B <sub>4</sub> in Human Skin Is Cyclooxygenase Independent;" (1995).

EXHIBIT NO.	DESCRIPTION
Exhibit 2017	Bateman, Adrian "Flesh and Bones of Pathology;" (2009).
Exhibit 2018	Krishnamoorthy, Sriram "Inflammation and disease progression;" (2006).
Exhibit 2019	Bouwmeester, Tewis et al. "A physical and functional map of the human TNF- $\alpha$ /NF- $\kappa$ B signal transduction pathway;" (2004).
Exhibit 2020	Page, Theresa et al. "Nonsteroidal Anti-Inflammatory Drugs Increase TNF Production in Rheumatoid Synovial Membrane Cultures and Whole Blood;" (2010).
Exhibit 2021	Vane, J.R., et al. "Mechanism of Action of Anti-Inflammatory Drugs;" (1996).
Exhibit 2022	Kurumbail, G., et al. "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents;" (1996).
Exhibit 2023	Marie, C., et al. "Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF) of interleukin-8 production by LPS and/or TNF $\alpha$ -activated human polymorphonuclear cells;" (1996).
Exhibit 2024	Trepicchio, William, et al. "Recombinant Human IL-11 Attenuates the Inflammatory Response Cytokine Through Down-Regulation of Proinflammatory Release and Nitric Oxide Production;" (1996).
Exhibit 2025	Patrick, Graham, "Drug Development;" (1995).
Exhibit 2026	Partial Testimony of Dr. Clayton Heathcock, Ph.D., <i>In Re OxyContin Antitrust Litigation</i> (2013).
Exhibit 2027	Testimony of Defendants' Expert Witness, Clayton H. Heathcock, Ph.D., <i>Astrazeneca UK Limited et al. v. Watson Laboratories, Inc. et al.</i> (2012).
Exhibit 2028	Hastings, R.C. et al., "Thalidomide analogs with potential activity in erythema nodosum leprosum;" (1979).
Exhibit 2029	Hastings, Robert, "Kellersberger Memorial Lecture 1979: Immunosuppressive/Anti—Inflammatory Thalidomide Analogues;" (1980).
Exhibit 2030	Henderson, Andrew, et al. "C/EBP Activators Are Required for HIV-1 Replication and Proviral Induction in Monocytic Cell Lines;" (1996).
Exhibit 2031	Herbein, Georges, et al. "The macrophage in HIV-1 infection: From activation to deactivation?;" (2010).
Exhibit 2032	Kalebic, Thea, et al. "Suppression of human immunodeficiency

EXHIBIT NO.	DESCRIPTION
	virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and <i>N</i> -acetylcysteine" (1991).
Exhibit 2033	Scifinder, "Thalidomide"
Exhibit 2034	Sekut, L., et al. "Anti-inflammatory activity of salmeterol: down-regulation of cytokine production;" (1995).
Exhibit 2035	Smith, Carla, et al. "Cyclosporin a Blocks Induction of Tumor Necrosis Factor-Alpha in Human B Lymphocytes;" (1994).
Exhibit 2036	Crutchley, David, et al. "Effects of Prostacyclin Analogs on the Synthesis of Tissue Factor, Tumor Necrosis Factor- $\alpha$ and Interleukin-1 $\beta$ in Human Monocytic THP-1 Cells <sup>1</sup> ;" (1994).
Exhibit 2037	Olivera, D.L., et al. "Effects of pyridinyl imidazole compounds on murine TNF- $\alpha$ production;" (1993).
Exhibit 2038	Rordorf-Adam, C. et al, "CGP 47969A: A novel inhibitor of the synthesis of inflammatory cytokines;" (1994).
Exhibit 2039	Helm, F., et al. "Comparative Teratological Investigation of Compounds structurally and pharmacologically Related to Thalidomide;" (1981).
Exhibit 2040	Barnhill, Raymond, et al. "Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions;" (1982).
Exhibit 2041	Schmahl, H.J. et al. "Pharmacokinetics of the Teratogenic and Nonteratogenic Thalidomide Analogs EM 12 and Supidimide in the Rat and Marmoset Monkey;" (1987).
Exhibit 2042	Hassan, Khairy, et al. "Antiinflammatory-Immunosuppressive Thalidomide Analogs;" (1981).
Exhibit 2043	King, Barry, et al. "Antiinflammatory-Immunosuppressive Thalidomide Analogs;" (1985).
Exhibit 2044	Sheskin, J., et al. "Trials with Thalidomide Derivatives in Leprosy Reactions;" (1968).
Exhibit 2045	Bruns, Robert, et al. "Rules for Identifying Potentially Reactive or Promiscuous Compounds;" (2012).
Exhibit 2046	Committee on Amines "Aromatic Amines: An Assessment of the Biological and Environmental Effects;" (1981).
Exhibit 2047	Utrecht, Jack "Reactivity and Possible Significance of Hydroxylamine and Nitroso Metabolites of Procaïnamide;" (1985).

Case IPR2015-01169  
Patent 5,635,517  
Patent Owner's Exhibit List

EXHIBIT NO.	DESCRIPTION
Exhibit 2048	Selleckchem.com "Pomadlidomide Datasheet."
Exhibit 2049	Pomalyst® July 2014 Product Information
Exhibit 2050	Delaware Department of State: Division of Corporations, "Coalition for Affordable Drugs"
Exhibit 2051	Delaware Department of State: Division of Corporations, "Coalition for Affordable Drugs VI LLC – Entity Details"
Exhibit 2052	The Wall Street Journal, "New Hedge Fund Strategy: Dispute the Patent, Short the Stock;" (2015).
Exhibit 2053	Business Insider, "Hedge Fund Manager Kyle Bass Is Going After Big Pharma And Its 'BS Patents;" (2015).
Exhibit 2054	Hayman Capital Management, L.P. June 2015 Form ADV Part 2A Brochure
Exhibit 2055	The Wall Street Journal, "Innovate or Else: Kyle Bass Strikes Again and Challenges Shire Patents;" (2015).
Exhibit 2056	Dallas Observer "Dallas' Erich Spangenberg is Very Proud to be America's Biggest Patent Troll;" (2013).
Exhibit 2057	January 2014 Spangenberg/IPNav email threatening IPRs
Exhibit 2058	January 2014 Spangenberg/IPNav threatened '501 patent IPR petition
Exhibit 2059	January 2014 Spangenberg/IPNav threatened '501 patent IPR declaration
Exhibit 2060	January 2014 Spangenberg/IPNav threatened '720 patent obviousness IPR petition
Exhibit 2061	January 2014 Spangenberg/IPNav threatened '720 patent obviousness IPR declaration
Exhibit 2062	January 2014 Spangenberg/IPNav threatened '720 patent anticipation IPR petition
Exhibit 2063	January 2014 Spangenberg/IPNav threatened '720 patent anticipation IPR declaration
Exhibit 2064	January 2014 Spangenberg/IPNav patent family tree
Exhibit 2065	July 2014 IRDP email threatening IPRs
Exhibit 2066	July 2014 IRDP threatened '501 patent IPR petition
Exhibit 2067	July 2014 IRDP threatened '501 patent IPR declaration

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.